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Overexpression of TIMP-1 in Embryonic Stem Cells Attenuates Adverse
Cardiac Remodeling Following Myocardial Infarction
Carley Glass and Dinender K. Singla
Burnett School of Biomedical Sciences, College of Medicine, University of Central Florida, Orlando, FL, USA

Transplanted embryonic stem (ES) cells, following myocardial infarction (MI), contribute to limited cardiac
repair and regeneration with improved function. Therefore, novel strategies are still needed to understand
the effects of genetically modified transplanted stem cells on cardiac remodeling. The present study evaluates whether transplanted mouse ES cells overexpressing TIMP-1, an antiapoptotic and antifibrotic protein,
can enhance cardiac myocyte differentiation, inhibit native cardiac myocyte apoptosis, reduce fibrosis, and
improve cardiac function in the infarcted myocardium. MI was produced in C57BL/6 mice by coronary artery
ligation. TIMP-1-ES cells, ES cells, or culture medium (control) were transplanted into the peri-infarct region
of the heart. Immunofluorescence, TUNEL staining, caspase-3 activity, ELISAs, histology, and echocardiography were used to identify newly differentiated cardiac myocytes and assess apoptosis, fibrosis, and heart
function. Two weeks post-MI, significantly ( p < 0.05) enhanced engraftment and cardiac myocyte differentiation was observed in TIMP-1-ES cell-transplanted hearts compared with hearts transplanted with ES cells and
control. Hearts transplanted with TIMP-1-ES cells demonstrated a reduction in apoptosis as well as an increase
( p < 0.05) in p-Akt activity compared with ES cells or culture media controls. Infarct size and interstitial and
vascular fibrosis were significantly ( p < 0.05) decreased in the TIMP-1-ES cell group compared to controls.
Furthermore, MMP-9, a key profibrotic protein, was significantly ( p < 0.01) reduced following TIMP-1-ES cell
transplantation. Echocardiography data showed fractional shortening and ejection fraction were significantly
( p < 0.05) improved in the TIMP-1-ES cell group compared with respective controls. Our data suggest that
transplanted ES cells overexpressing TIMP-1 attenuate adverse myocardial remodeling and improve cardiac
function compared with ES cells that may have therapeutic potential in regenerative medicine.
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INTRODUCTION
Cell transplantation strategies using renewable sources
of cardiac myocytes to repair damaged myocardium,
replace lost cardiac cells, and prevent remodeling following myocardial infarction (MI) has gained significant
attention. We, as well as others, have shown that transplanted embryonic stem (ES) cells post-MI have the
potential to engraft, differentiate into cardiac-specific
cell types, limit adverse myocardial remodeling, and
improve heart function (3,14,33,34). However, inhibition
of adverse cardiac remodeling following cell transplantation is minimal relative to normal heart architecture and
overall cardiac function. Therefore, novel approaches are
needed to augment the efficacy by which transplanted ES
cells enhance cardiac repair in order to optimize cardiac
regain of function following cell transplantation therapy.
Following myocardial infarction, ventricular architectural remodeling consequent to MI is characterizedby various physiological and cellular changes including cardiac

cell death via apoptosis and necrosis, fibrosis, and hypertrophy leading to end stage heart failure (2,15,19,25,34).
In response to myocardial cell death post-MI, increased
expression of extracellular matrix (ECM) proteins, specifically collagen types I and III, occurs evoking fibrosis
formation (23,40). Fibrosis within the injured myocardium
causes stiffening of the heart and overall systolic and diastolic dysfunction. Matrix metalloproteinases (MMPs) are
a family of endopeptidases, which play a fundamental role
in the degradation and aberrant production of ECM proteins leading to alterations in ventricular architect post-MI.
Tissue inhibitors of metalloproteinases (TIMPs) are innate
protease inhibitors of MMPs. TIMP-1, the most extensively characterized TIMP, is not only a well-documented
antifibrotic protein (6,7,12) but also has recently been
shown to exhibit antiapoptotic characteristics in noncardiac cell types such as breast epithelial cells (22,35,44).
Moreover, we were the first to report that TIMP-1 is a cytoprotective released factor from ES cells, which prevents
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H2O2-induced apoptosis in vitro in cardiomyoblasts (H9c2
cells) (35). However, whether TIMP-1, when overexpressed in transplanted ES cells, can impact adverse cardiac remodeling post-MI by blunting host myocardium
apoptosis and fibrosis has yet to be delineated.
In the present study, we hypothesize that ES cells overexpressing TIMP-1 (TIMP-1-ES cells), following transplantation into the infarcted myocardium, will attenuate
apoptosis and fibrosis along with improving cardiac function. To accomplish this hypothesis, we generated ES cells
overexpressing TIMP-1 (TIMP-1-ES cells), transplanted
them into the infarcted myocardium, and evaluated their
impact on engraftment, cardiac myocyte differentiation,
apoptosis, fibrosis, and associated cardiac function. Our
data show that TIMP-1-ES cells engraft and differentiate
into cardiac mycoytes in the infarcted myocardium. We
also suggest transplanted TIMP-1-ES cells post-MI significantly inhibit cardiac myocyte apoptosis compared with
ES cells and the antiapoptotic effect of TIMP-1 is, in part,
mediated through the Akt pathway. Furthermore, we demonstrate that transplanted TIMP-1-ES cells inhibit both
interstitial and vascular fibrosis in the infarcted myocardium. Finally, we show that transplantation of TIMP-1-ES
cells post-MI significantly enhances cardiac function.
MATERIALS AND METHODS
ES Cell Culture
CGR8 ES cells with or without TIMP-1 were cultured
and maintained on 0.1% gelatin-coated tissue culture plates
in Dulbecco’s minimum essential medium (DMEM) growth
media supplemented with leukemia inhibitory factor (LIF),
sodium pyruvate, glutamine, penicillin/streptomycin, nonessential amino acids, b-mercaptoethanol, and 15% ES qualified fetal bovine serum as we previously reported (38).
TIMP-1-ES Cell Generation
The mammalian expression vector (pTurboFP635-C)
encoding red fluorescent protein (RFP) was purchased
from Evrogen (Moscow, Russia). The cDNAs coding
mouse TIMP-1 gene were generated by PCR cloning
using high-fidelity DNA polymerase and PCR primers (forward, 5¢-AGAGCAGATACCATGATG-3¢ and
reverse, 5¢-GAAGGCTTCAGGTCATCG-3¢). The PCR
product was cloned to the Bgl II and BamH l site of the
pTurboFP635 C-terminus as a single open reading frame
to code for a TIMP-1/RFP fusion protein. The expression
vector contained a neomycin resistance gene for selection
of stable transfectants in CGR8 ES cell lines. The sequence
of mouse TIMP-1 gene was confirmed by restriction
enzyme digestion and DNA sequencing analysis.
CGR8 mouse ES cells were transfected with the
TIMP-1 expression vector using Lipofectamine 2000
(Invitrogen). Selection media containing 100 mg/ml of
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the selective antibiotic G418 (Invitrogen) was added 48 h
posttransfection. Selection medium was changed every
48 h, and cells were maintained for 2–3 weeks. Thereafter,
G418-resistant ES cell colonies (labeled TIMP-1-ES
cells) were selected, expanded, and maintained in ES cell
culture medium. TIMP-1-ES cell clones were confirmed
with elevated TIMP-1 protein expression as compared to
parental CGR8 ES cells through Western blot analysis
using a primary antibody against TIMP-1 (sc-5538, Santa
Cruz) followed by incubation with goat anti-rabbit IgG
secondary antibody (sc-2004, Santa Cruz).
TIMP-1 ELISA
Levels of secreted TIMP-1 were measured using a
Ray Bio® Mouse TIMP-1 ELISA kit (ELM-TIMP1-001)
as per the manufacturer’s instructions. In brief, 1 week
posttransfection and selection, medium was collected
from tissue culture dishes containing growing ES and
TIMP-1-ES cells. Samples were added for 2.5 h to the
precoated wells, washed and incubated with biotinylated
antibody for an additional hour. Following washings,
horse radish peroxidase (HRP)-conjugated streptavidin
solution was added for 45 min followed by incubation
with the substrate solution for 30 min. Immediately thereafter, a stop solution was added and the color intensity
was measured at 450 nm. The values obtained from the
ELISA were corrected for the total protein concentration
of each sample as estimated by the Bradford assay.
MI and Cell Transplantation
All mice were maintained and used as approved by the
institutional animal review board. C57BL/6 mice (8–10
weeks old) were divided into four study groups (n = 8 per
group): Sham, MI + cell culture media (MI + CC), MI + ES
cells, and MI + TIMP-1-ES cells. In brief, mice were
anesthetized, endotracheally intubated, and ventilated
using a rodent MiniVent (Harvard Apparatus). Anesthesia
was maintained using 2.5% isoflurane throughout the
procedure. Left thoracotomy was performed, and the
descending left coronary artery was permanently ligated
as we reported previously (18). Following ligation, two
intramyocardial injections of 10 ml of medium containing
2.5 ´ 104 TIMP-1-ES cells or ES cells were delivered into
the peri-infarct region. The chest was then closed, lungs
expanded, and mice were weaned from the ventilator and
extubated. Sham group animals received all identical surgical procedures with the exception of no coronary artery
ligation. Mice received postoperative care, including
analgesia (buprenorphine, 0.5 mg/kg), for 2 days or until
normal behavior resumed. Day 1 (D1) and D14 following
surgery, mice were sacrificed by pentobarbital (80 mg/kg)
followed by cervical dislocation. Hearts were removed,
transversely cut, and fixed in 4% paraformaldehyde for
further evaluation.
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Histopathology
Heart tissue was embedded and sectioned as previously described (34). In brief, heart tissue was embedded in paraffin blocks, cut in serial sections (5 mm), and
placed onto Colorfrost Plus microscope slides (Fisher
Scientific). Heart sections were deparaffinized using
room temperature xylene followed by sequential incubation in 100%, 95%, and 70% ethanol for 3 min and
washed with distilled water. Heart sections were then
stained with Mason's trichrome. Left ventricular (LV)
infarct size was quantified by measuring the total LV
infarct area/LV area ´ 100%. To quantify interstitial fibrosis, infarct, peri-infarct, and noninfarct regions of the
heart were examined, and fibrosis was quantified by measuring the total blue area/total heart area ´ 100%. Vascular
fibrosis was quantified by measuring vascular fibrosis/
vessel area ´ 100% in one to two sections from five to
eight hearts per group. All fibrosis measurements were
made using NIH ImageJ software.
Immunohistochemistry
To quantify engrafted transplanted cells at D1 and D14
following MI, heart sections were deparaffinized as aforementioned and immunohistochemically stained using
primary antibodies against RFP (AB232, Evrogen) and
octamer-binding transcription protein 3/4 (Oct 3/4; sc-
5279, Santa Cruz). Heart sections were then incubated
with Alexa 488- or Alexa 568-conjugated secondary antibodies (Invitrogen), respectively. Sections were washed,
air dried, and mounted with Antifade Vectashield mounting medium. Colocalization of RFP and Oct 3/4-positive
cells were counted as engrafted transplanted cells in one to
two heart sections from n = 6–8 animals/group. To quantify the amount of differentiated cardiac myocytes from
transplanted cells at D14, hearts were immunohistochemi
cally stained with primary antibodies against sarcomeric
a-actin (A2172, Sigma) and RFP (AB232, Evrogen) followed by incubation with appropriate secondary antibodies. Cells positive for both sarcomeric a-actin and RFP
were counted as newly differentiated cardiac myocytes
derived from transplanted stem cells. Visualization of
engrafted and differentiated cells was performed using
Olympus fluorescent and Leica TSC SP2 laser scanning
confocal microscopes.
TUNEL and Cardiac a-Actin Staining
Terminal deoxynucleotidyl transferase dUTP nick end
labeling (TUNEL) staining was performed as previously
described (36). In brief, heart sections were deparaffinized and permeabilized with proteinase K (25 mg/ml
in 100 mM Tris–HCl). The TUNEL assay kit (TMR red;
Roche Applied Biosystems) was used as per the manufacturer’s instructions to detect host myocardium apoptotic
nuclei. Apoptotic cells were colabeled with cardiac a-actin
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(A2172, Sigma) to detect apoptosis within cardiac myocytes. Heart sections were then mounted with Antifade
Vectashield mounting medium containing 4¢,6-diamidino2-phenylindole (DAPI; Vector Laboratories) for nuclear
staining and observed under Olympus and confocal
microscopes: percentage of total apoptotic nuclei = (total
number of red stained apoptotic nuclei)/(total number of
blue stained nuclei with DAPI) ´ 100. Additionally, the
percentage of apoptotic nuclei in cardiac myocytes was
also determined by (total number of red stained apoptotic
nuclei colocalized with sarcomeric a-actin)/(total number
of blue stained nuclei with DAPI) ´ 100. Total apoptotic
nuclei and apoptotic cardiac myocyte nuclei were quantitated in the infarct and peri-infarct regions of the heart in
one to two sections from five to eight hearts from each
group. These cell counts were performed as previously
reported by us and others (9,13,37).
Caspase-3 Activity Assay
Caspase-3 activity was quantitated using a caspase-3
colorimetric activity assay kit (K106-200, BioVision).
Hearts were homogenized in RIPA buffer containing protease inhibitor cocktail (Sigma), phenylmethylsulfonyl
fluoride (PMSF) (1 mM), sodium orthovandate (2 mM),
and sodium fluoride (5 mM), collected, and centrifuged
at 11,766 rpms for 5 min. The supernatant was removed,
and protein concentration estimation was performed
using a Bio Rad assay. Manufacturer’s instructions were
followed to complete the activity assay. Developed blue
color was measured in a microtiter plate reader (Bio Rad)
at 405 nm. Caspase-3 activity graph was plotted as arbitrary units (A.U.).
Phosphorylated Akt Activity Assay
Phosphorylated Akt (p-Akt) was quantitated using a
phospho-Akt1 (PAN) ELISA kit (X1844k, Exalpha Bio
logical) as previously described and detailed in the instruction manual provided with the kit (37). In brief, hearts
were homogenized, and proteins were estimated by the
Bradford method. Samples (25 ml) and sample diluents
(75 ml) were added to the wells labeled with captured
antibodies provided in the kit for 2 h. Following washing, samples were incubated with detector antibody for
2 h, HRP conjugate for 30 min, and substrate for 30 min
with washings in between each step. A stop solution was
added and the developed yellow color was measured in a
microtiter plate reader (Bio Rad) at 450 nm. Phospho-Akt
graph was plotted as detailed in the kit.
MMP-9 Immunoassay
MMP-9 concentration was determined by an enzymelinked immunoassay (MMPT90, R&D Systems). In brief,
hearts from n = 8 animals/group were homogenized, and
protein concentrations were estimated as aforementioned.
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Samples were loaded into monoclonal MMP-9-immobilized
antibody-coated wells provided in the kit for 2 h. Follow
ing washings, a conjugate (polyclonal antibody for mouse
MMP-9) was added for an additional 2 h. Again the wells
were washed, and a substrate solution was added to each
well for 30 min followed by the addition of a stop solution.
A color reaction developed proportional to the amount of
bound MMP-9 and was measured in a microtiter plate
reader (Bio Rad) at 450 nm. MMP-9 graph was plotted as
arbitrary units (A.U.).
Echocardiography
Cardiac function for all mice groups was assessed
noninvasively by transthoracic echocardiography at D14.
Mice were anesthetized with 2% isoflurane, placed and
maintained on a temperature-controlled heating pad, and
the chest was shaved. Echocardiography was performed
using a Phillips Sonos 5500 Ultrasound system with a
15-6L hockey stick transducer. Left ventricular internal
dimension-diastole (LVIDd), left ventricular internal
dimension-systole (LVIDs), fractional shortening (LVIDdLVIDs/LVIDd ´ 100), and ejection fraction [left ventricu
lar volume at end diastole (EDV) – left ventricular volume at end systole (ESV)/EDV] were calculated using
the Teichholz formula (41) at the midpapillary muscle
level in short-axis view.
Statistical Analysis
All values presented as a mean ± SEM. Statistical analysis was performed using the students’ t-test, one-way
analysis of variance (ANOVA), and the Bonferroni test.
Statistical significance was assigned when p < 0.05.
RESULTS
To elucidate the impact of TIMP-1 in transplanted ES
cells post-MI on cardiac remodeling and function, we
overexpressed TIMP-1 (Fig. 1A–C) in CGR8 ES cells.
Following selection with G418, TIMP-1-ES cells were
maintained in cell culture for 10–12 weeks. To determine
stable transfection, Western blot analysis was performed,
and our data shows a ~49 kDa fusion protein band representative of TIMP-1/RFP expression in TIMP-1-ES
cells compared to parental ES cells ( p < 0.001) (Fig. 1D).
Additionally, to understand whether TIMP-1 is secreted
in the conditioned media (CM) obtained from ES and
TIMP-1-ES cells, a TIMP-1 ELISA was performed on
ES-CM and TIMP-1-ES-CM. Our quantitative data show
a dramatic change in secreted TIMP-1 in TIMP-1-ES-CM
relative to ES-CM ( p < 0.05) (Fig. 1E).
Enhanced Engraftment and Cardiac Myocyte
Differentiation in TIMP-1-ES Cell Transplanted Hearts
To assess the impact of TIMP-1 overexpression
in transplanted ES cells on engraftment into the host
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myocardium, heart sections were double immunolabeled
with antibodies against RFP to detect donor transplanted
cells and Oct 3/4, a marker indicative of pluripotent
stem cells (Fig. 2). Figure 2A and E shows Oct 3/4positive cells in red, Figure 2F shows RFP-positive cells
in green whereas no such cells are present in the MI + CC
group (Fig. 2B), DAPI is shown in blue in Figure 2C
and G, and merged images are depicted in Figure 2D
and H. The boxed area in Figure 2H is enlarged to show
colocalization of Oct 3/4, RFP, and DAPI in the TIMP1-ES cell group. At D1, no significant difference was
observed in the amount of engrafted transplanted ES or
TIMP-1-ES cells (Fig. 2I). However, at D14 a dramatic
difference in the amount of engrafted TIMP-1-ES cells
was quantified relative to the amount of engrafted ES
cells ( p < 0.05) (Fig. 2J).
To quantify cardiac myocyte differentiation from
transplanted ES and TIMP-1-ES cells, heart sections
were double immunolabeled with antibodies against RFP
and the cardiac myocyte marker, sarcomeric a-actin.
Colocalization of RFP-positive cells with a-actin positive
cells were counted as newly differentiated cardiac myocytes from transplanted stem cells (Fig. 3). Figure 3A,
E, I, and M shows a-actin-positive cardiac myocytes
(red), Figure 3J and N shows transplanted donor cells
(green) whereas no such cells were present in the sham
or MI + CC group (Fig. 3B, F), Figure 3C, G, K, and
O shows total nuclei stained with DAPI (blue), and
Figure 3D, H, L, and P shows merged images of triplelabeled sections depicting differentiated cardiac myocytes
from donor transplanted cells. Upon quantification, we
reveal TIMP-1-ES cell-transplanted hearts contain significantly more donor-differentiated cardiac myocytes
compared to ES cell-transplanted hearts as depicted in
Figure 3Q (p < 0.05).
Reduced Infarct Region Following TIMP-1ES Cell Transplantation
Representative whole-heart images depicting infarct
size are represented in Figure 4A. Following quantification of infarct size, we reveal that the dramatic increase
in infarct dimensions observed within the control MI + CC
group was significantly blunted following transplantation of ES and TIMP-1-ES cells ( p < 0.001) (Fig. 4B).
Furthermore, our data demonstrate the extent of infarcted
region within TIMP-1-ES cell transplanted hearts was
significantly decreased compared to ES cell-transplanted
hearts suggesting TIMP-1-ES cells are superior in reducing
infarct size compared with ES cells ( p < 0.01) (Fig. 4B).
Transplanted TIMP-1-ES Cells Prevent Apoptosis
in the Infarcted Heart
To determine whether transplanted ES cells over
expressing TIMP-1 inhibit apoptosis compared to ES cells
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Figure 1. TIMP-1 vector and the generation of TIMP-1-ES cells. (A) Tissue inhibitor of metalloproteinases-1 (TIMP-1) cDNA was
cloned into the pTurboFP635-C expression vector encoding red fluorescent protein (RFP). TIMP-1-ES (TIMP-1-embryonic stem)
cells were selected following incubation with the selective antibiotic G418. Representative photomicrographs of TIMP-1-ES cells
in bright field microscopy (B) and under fluorescence microscopy (C) to demonstrate RFP expression. (D) Representative photomicrographs of Western blot. Histogram shows significant overexpression of TIMP-1 in TIMP-1-ES cells relative to parental ES cells.
*p < 0.001 versus ES cells. (E) Histogram shows quantitative analysis of secreted TIMP-1 in ES and TIMP-1-ES cells. *p < 0.05 versus
ES cells. MCS, multiple cloning site.

in the host myocardium, TUNEL staining was performed
(Fig. 5). At D14, there was a significant decrease in
TUNEL-positive nuclei post-MI in the infarct and peri-
infarct regions of hearts transplanted with ES cells
compared to controls ( p < 0.001) (Fig. 5Q). Moreover,
TIMP-1-ES cell-transplanted hearts contained significantly fewer total apoptotic nuclei compared to ES cell
and cell culture medium groups (mean ± SEM; MI + TIMP1-ES cells: 0.63 ± 0.06% vs. MI + ES cells: 0.94 ± 0.07%
and MI + CC: 1.55 ± 0.12%, TUNEL positive/total nuclei,
p < 0.05) (Fig. 5Q). Additionally, heart sections were colabeled with sarcomeric a-actin to demonstrate and quantitate apoptosis within cardiac myocyte nuclei (Fig. 5M–P).
Our data show apoptotic cardiac myocyte nuclei were significantly reduced in hearts transplanted with TIMP-1-ES
cells compared with ES cell and media-transplanted hearts

( p < 0.05) (Fig. 5R). Next, to strengthen our TUNEL data,
a caspase-3 colorimetric assay was performed on heart
homogenates from each group. There was a significant
decrease in caspase-3 activity in hearts treated with TIMP1-ES cells post-MI compared to hearts transplanted with
ES cells or medium alone (mean ± SE; MI + TIMP-1-ES
cells: 171.75 ± 2.56 vs. MI + ES cells: 188.50 ± 1.80 and
MI + CC: 203.00 ± 4.36, p < 0.05) (Fig. 6A).
TIMP-1 Enhances p-Akt Activation in Post-MI Hearts
Previous studies have shown that mechanisms of inhibited apoptosis involve the activation of cell survival pathways including p-Akt (38). Our data demonstrate that hearts
transplanted with TIMP-1-ES cells did in fact have significant increase in the activation of p-Akt compared to
hearts transplanted with ES cells and medium (mean ± SE;
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Figure 2. Enhanced engraftment of TIMP-1-ES cells in the infarcted myocardium. Representative photomicrographs showing heart
sections stained with anti-octamer binding transcription protein 3/4 (Oct 3/4) for pluripotent cells in red (A and E), donor transplanted cells in green (B and F), nuclei stained with DAPI in blue (C and G), and the merged image (D and H). Scale bar: 20 mm.
(I) Quantitative analysis of engrafted cells at D1 following myocardial infarction (MI). (J) Significant increase in engrafted TIMP1-ES cells at D14. *p < 0.05 versus MI + ES cells. CC, cell culture media.

MI + TIMP-1-ES cells: 6.99 ± 0.22 vs. MI + ES cells:
5.75 ± 0.16 and MI + CC 4.61 ± 0.25, p < 0.05) (Fig. 6B),
suggesting upregulation of cell survival pathways.
Reduced Fibrosis Following MI in TIMP-1-ES Cell
Group (Fig. 7)
Interstitial fibrosis in the infarcted heart sections was
measured at D14 and representative photomicrographs
from each group are depicted in Figure 7A–D. Compared
to medium alone, ES cell-transplanted hearts had a signifi
cant reduction in the amount of total interstitial fibrosis
( p < 0.01) (Fig. 7I). Furthermore, the reduced interstitial
fibrosis observed in TIMP-1-ES cell-transplanted hearts
was significant when compared to ES cell and control
hearts (mean ± SE; MI + TIMP-1-ES cell: 0.23 ± 0.03 mm2

vs. MI + ES cells: 0.47 ± 0.02 mm2 and MI + CC: 0.90 ±
0.00 mm2, p < 0.01) (Fig. 7I).
Next, quantitative assessment of vascular fibrosis
(Fig. 7E–H) revealed ES cell-transplanted hearts had a significant decrease in the amount of vascular fibrosis compared to medium alone ( p < 0.001) (Fig. 7J). Furthermore,
the attenuation of vascular fibrosis in TIMP-1-ES celltransplanted hearts reached statistical significance when
compared to ES cells ( p < 0.05) (Fig. 7J).
To determine whether inhibition of fibrosis was
associated with changes in MMP-9, a well-documented
MMP involved in the pathogenesis of MI, MMP-9 was
quantified using an enzyme-linked immunoassay. Hearts
transplanted with ES cells demonstrated significantly
reduced MMP-9 concentration compared with control
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Figure 3. TIMP-1 enhances differentiation of ES cells into cardiac myocytes. Representative photomicrographs showing heart sections stained with anti-a-actin for cardiac myocytes in red (A, E, I, and M), anti-RFP for donor transplanted cells in green (B, F, J,
and N), nuclei stained with DAPI in blue (C, G, K, and O), and the merged image (D, H, L, and P) showing coexpression of a-actin
and RFP indicating differentiated donor cells. Scale bar: 20 mm. (Q) Quantitative analysis of differentiated donor ES cells into cardiac
myocytes 2 weeks following MI. *p < 0.05 versus ES cells.

Figure 4. TIMP-1 reduces infarct size following MI. (A) Representative photomicrographs of hearts
demonstrating infarct size from C57BL/6 mice 2 weeks post-MI or sham surgery. Scale bar: 500 mm.
(B) Histogram shows infarct size was significantly reducing following transplantation of TIMP1-ES cells. *p < 0.001 versus MI + CC and #p < 0.001 versus MI + CC and MI + ES cells. LV = left
ventricle.
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Figure 5. Effects of transplanted ES cells overexpressing TIMP-1 on host cardiac myocyte apoptosis in C57BL/6 mice. ES and TIMP1-ES cells were transplanted post-MI and hearts were examined for apoptosis 2 weeks following cell transplantation. Representative
photomicrographs of total nuclei stained with DAPI in blue (A–D), apoptotic nuclei stained with Terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) in red (E–H), and merged nuclei in pink (I–L). Scale bar: 100 mm. (M–P) Set of represen
tative photomicrographs of section labeled with sarcomeric a-actin (M), apoptotic nuclei stained with TUNEL in red (N), total
nuclei stained with DAPI in blue (O), and merged image (P) demonstrating apoptosis occurs within the cardiac myocyte. Scale bar:
50 mm. Boxed area in (O) enlarged to show colocalization of sacromeric a-actin, TUNEL-positive nucleus, and DAPI. (Q) Total
apoptotic nuclei in the infarct and peri-infarct regions of the heart in one to two sections from five to eight hearts from each group.
*p < 0.001 versus MI + CC, #p <0.05 versus MI + CC and MI + ES cells. (R) Quantitative cardiac myocyte apoptotic data. *p < 0.01 versus MI + CC, #p < 0.05 versus MI + CC and MI + ES cells.

hearts ( p < 0.01) (Fig. 7K). Moreover, MMP-9 concentration within TIMP-1-ES cell-transplanted hearts was significantly less compared to hearts transplanted with ES cells
or media (mean ± SE; MI + TIMP-1-ES cells: 21.19 ± 1.27
vs. MI + ES cells: 41.64 ± 3.83 and MI + CC: 63.81 ± 8.18,
p < 0.01) (Fig. 7K).
Overexpression of TIMP-1 Improves Cardiac Function
Post-MI
To evaluate the cardiac functional consequences of
transplanted TIMP-1-ES cells post-MI, two-dimensional
echocardiography was performed. Obtained primary raw
data are depicted in Figure 8A. Cumulative quantitative

data revealed that, although a trend of decreased LVIDd
was observed between TIMP-1-ES cell-transplanted
mice and ES cell or CC-transplanted mice, statistical
significance was not attained (Fig. 8B). Conversely, left
ventricular dimensions during systole were significantly
reduced following transplantation of TIMP-1-ES cells
relative to mice transplanted with ES cells or CC ( p <
0.05) (Fig. 8C). Cardiac function data at D14 further suggest mice receiving ES cell transplantation following MI
had significantly improved fractional shortening compared to medium alone ( p < 0.001) (Fig. 8D). Moreover,
mice transplanted with TIMP-1-ES cells post-MI had significantly increased fractional shortening when compared
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Figure 6. Effects of TIMP-1-ES cell transplantation on caspase-3 and p-Akt expression. (A) Quantitative analysis of caspase-3
activity in hearts transplanted with and without stem cells. *p < 0.05 versus MI + CC, #p < 0.05 versus MI + CC and MI + ES cells.
(B) Quantitative analysis of phospho-Akt activation. *p < 0.01 versus MI + CC, #p < 0.01 versus MI + CC and MI + ES cells.

to mice transplanted with ES cells and medium post-MI
at D14 (mean ± SE; MI + TIMP-1-ES cells: 44.81 ± 0.70%
versus MI + ES cells: 41.01 ± 0.61% and MI + CC: 31.30 ±
0.88%, p < 0.05) (Fig. 8D).
End diastolic and systolic volumes are depicted in
Figure 8E and F, respectively, for all study groups. As
a dramatic reduction in ejection fraction was observed
in MI + CC mice, this decrease was significantly blunted
in mice transplanted with TIMP-1-ES and ES cells ( p <
0.001) (Fig. 8G). Notably, mice transplanted with TIMP1-ES cells additionally had significantly enhanced ejection fraction when compared with ES cell-transplanted
mice ( p < 0.05) (Fig. 8G).
DISCUSSION
Many stem cell types examined thus far including skeletal myoblasts, bone marrow stem cells, bone marrowderived hematopoietic stem cells, endogenous cardiac
stem cells, mesenchymal stem cells, induced pluripotent stem (iPS) cells, and ES cells have shown improved
cardiac function following transplantation post-MI
(16,26,27,30,33). Improvement in cardiac function in
past studies was demonstrated by newly differentiated
cardiac myocytes and inhibition of apoptosis and fibrosis. However, observed effects of stem cell transplantation following MI was not enough to provide complete
protection required to reestablish normal heart function. Therefore new strategies, such as modulation of
ES cells using antiapoptotic and antifibrotic genes, are
required. In the present study, we transfected ES cells
with TIMP-1, an antiapoptotic and antifibrotic gene,
transplanted them into the myocardium post-MI, and
evaluated their effects on cardiac myocyte engraftment

and differentiation, myocardial remodeling (apoptosis
and fibrosis), and cardiac function.
Well-documented, endogenous TIMP-1 has been
shown to be found within the extracellular matrix,
membrane bound at the cell surface, and localized to
the nucleus (22,31). The discriminating benefit propagated by constitutively active vector-driven TIMP-1
expression in ES cells is that TIMP-1 has the potential to exert its effects in an autocrine-mediated manner protecting transplanted ES cells from cell death or
through paracrine mechanisms protecting the injured
myocardium. We show that following transfection with
the TIMP-1-RFP construct, the fusion proteins are
abundantly expressed in and secreted by TIMP-1-ES
cells. Previous studies have shown similar results indicating generated TIMP-1-GFP or TIMP-1-RFP fusion
constructs are processed analogous to endogenous
TIMP-1 (11,31).
The feasibility of exogenous transplanted cells to
engraft into the infarcted myocardium is well documented
(4,16,29,33). ES cells, derived from the inner cell mass
of the blastocyst, are advantageous for nonautologous
cell transplantation in that they confer minimal immuno
reactivity consequent to the limited number to major
histocompatibility complex surface proteins. Our study
provides evidences indicating the enhanced survival of
TIMP-1-ES cells in the injured myocardium following transplantation. Notably, these data for the first time
suggest that a significant increase in TIMP-1-ES cells
remain engrafted in the myocardium 2 weeks following
transplantation contrary to the common observation that
the majority of transplanted cells die within the first few
days (5,32,48).
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Figure 7. Effects of transplanted ES cells overexpressing TIMP-1 on interstitial and vascular fibrosis. Representative photomicrographs from sections stained with Masson’s trichrome 2 weeks following coronary artery ligation demonstrating interstitial (A–D) and
vascular (E–H) fibrosis. Scale bar: 100 mm. (I) Quantitative total interstitial fibrosis per section. *p < 0.01 versus MI + CC, #p < 0.05
versus MI + CC and MI + ES cells. (J) Quantitative analysis of vascular fibrosis in heart sections. *p < 0.001 versus MI + CC, #p < 0.01
versus MI + CC and MI + ES cells. VA, vessel area; VF, vessel fibrosis. (K) Average matrix metalloproteinase-9 (MMP-9) concentration within hearts from each group. *p < 0.01 versus MI + CC, #p < 0.05 versus MI + CC and MI + ES cells.

Regeneration of the infarcted heart is imperative to
restoring the heart to pre-MI homeostasis. Intensive in
vitro and in vivo research is underway using various factors to enhance and promote cardiac myocyte differentiation from stem cell populations (10,39,46,47). In this
study, we have shown that our RFP-positive donor cells
were elongated, nucleated, striated, and positive for sarcomeric a-actin. These characteristics of our RFP-positive
cells indicate that not only do the transplanted cells survive in the injured myocardium but also differentiate into
mature cardiac myocytes. Moreover, we have shown for
the first time enhanced cardiac myocyte differentiation
from transplanted ES cells post-MI by overexpression
of TIMP-1. Our results are consistent with recent findings demonstrating the ability of TIMP-1 to promote

oligodendrocyte, germinal center B cell, and UT-7 erythroid cell differentiation (8,17,28).
Next, we wanted to understand the effects of transplanted TIMP-1-ES cells on endogenous cardiac apoptosis. Well established, apoptosis is a major mechanism
by which cardiac myocyte cell death occurs following
MI leading to hypertrophy, fibrosis, and ultimately poor
cardiac function. TIMP-1 has recently been identified as
antiapoptotic in various cell lines including human osteosarcoma cells (MG-63), mouse bone marrow stromal
cells (MBA-1), murine MC3T3-E1 osteoblasts, human
breast epithelial cells, and rat cardiomyoblasts (H9c2)
(24,35,43,44). The present study demonstrates a significant reduction in apoptosis in the host myocardium following transplantation with TIMP-1-ES cells compared
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Figure 8. TIMP-1 overexpressed in ES cells improves cardiac function in C57BL/6 mice. Echocardiography was performed D14
following MI and fractional shortening and ejection fraction were quantified. (A) Primary raw data obtained from echocardiography
analysis. (B) Average Left ventricular internal dimension-diastole (LVIDd). (C) Average LVIDs (systole). *p < 0.01 versus MI + CC
and #p < 0.05 versus MI + CC and MI + ES cells. (D) Average fractional shortening at 2 weeks post-MI for all treatment groups.
*p < 0.001 versus MI + CC, #p < 0.05 versus MI + CC and MI + ES cells. (E) Average EDV (left ventricular volume at end diastole).
*p < 0.05 versus MI + CC. (F) Average ESV (left ventricular volume at end systole). *p < 0.001 versus MI + CC and #p < 0.05 versus
MI + CC and MI + ES cells. (G) Quantified average ejection fraction. *p < 0.001 versus MI + CC, #p < 0.05 versus MI + CC and MI + ES
cells. Data set is from n = 8 different animals/group.

to ES cells confirmed by TUNEL staining and caspase-3
activity assay. Our data are in accordance with a previously published study suggesting TIMP-1 conditioned
media (CM) prevents H2O2-induced apoptosis in an in
vitro model similar to ischemic myocardium (35).
Previous studies have reported a positive correlation
between TIMP-1 and activation of the Akt signaling
cascade-promoting breast epithelial and UT-7 erythroid
cell survival (1,21). Our present study also provides evidence indicating hearts transplanted with TIMP-1-ES
cells had significant activation of p-Akt compared to

hearts transplanted with ES cells and medium controls.
Although future detailed studies are necessitated to determine the exact mechanisms of the TIMP-1 antiapoptotic
influence, our findings are in corroboration with previous studies suggesting mechanisms of inhibited apoptosis
involve the activation of cell survival pathways including
Akt (38).
Fibrosis, a major contributor to adverse cardiac
remodeling, is consequent to increased MMP activation
post-MI, which leads to ECM degradation, increased collagen deposition, stiffening of the heart, and ultimately
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poor cardiac function. In the present study, our cardiac
fibrosis data (interstitial and vascular fibrosis) demonstrate significantly reduced fibrosis in hearts treated with
TIMP-1-ES cells compared with hearts transplanted with
ES cells. Additionally, hearts transplanted with TIMP1-ES cells contained significantly less MMP-9 compared
with ES cell and CC groups post-MI. These data are
supported by previous studies indicating a reduction in
MMP-9 expression in the presence of TIMP-1 overexpression (42). Following an MI, increased MMP activation is
not paralleled by an increase in TIMP-1 expression (45).
Therefore, we suggest significant reduction in the post-MI
fibrosis observed in the TIMP-1-ES cell-transplanted
hearts compared to ES cell-transplanted hearts may be
attributable to inhibition of MMP-9 through overexpression of TIMP-1. However, further studies are required to
define these mechanisms.
Finally, we needed to determine whether an increase
in newly differentiated cardiac myocytes and inhibition of apoptosis and fibrosis in the host myocardium
contribute to a decrease in infarct size and ultimately
improve cardiac function following MI in TIMP-1-ES
cell-transplanted animals. Infarcted myocardium contributes to aberrant left ventricular stiffness and diastolic
dysfunction post-MI. Within the current study, we have
shown a large infarct scar post-MI in the MI + CC control
group. However, the infarct scar region was significantly
diminished following TIMP-1-ES cell transplantation.
Conceivably, we suggest that increased engraftment and
differentiation following TIMP-1-ES cell transplantation repopulated the heart with additional functional
cardiac myocytes, thereby reducing the infarct scar size.
Moreover, in the present study, our data demonstrate that
2 weeks following MI, mice transplanted with TIMP1-ES cells had significantly increased fractional shortening and ejection fraction compared to mice transplanted
with ES cells or cell culture medium. We recognize that
the mechanisms of improved cardiac function are complex and multifactorial. We do however suggest that the
decrease in apoptosis and fibrosis, which is correlated
with a decrease in infarct scar size, is directly related to
the modulation of cardiac function observed within the
current study. It is possible also to assert that improvement in ventricular function may be consequent to bene
ficial autocrine and paracrine mechanisms of TIMP-1
leading to continual differentiation of cardiac myocytes
from transplanted TIMP-1-ES cells and protection of
the host myocardium respectively leading to a decreased
infarct size and ultimately cardiogenesis. These results
are consistent with recent findings demonstrating regeneration of the infarcted myocardium following transplantation of ES cells (20,32,34). Findings from this study
indicate that transplantation of TIMP-1-ES cells attenuate
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adverse cardiac remodeling and improve heart function
following MI.
In conclusion, the major findings of the present study
involving TIMP-1-overexpressing ES cells relative to ES
cells include the following for the first time: (1) engraftment and differentiation into cardiac myocytes are significantly upregulated in transplanted TIMP-1-ES cells,
(2) infarct size is significantly diminished in TIMP-1-ES
cell-transplanted hearts, (3) TIMP-1-ES cells significantly
inhibit cardiac apoptosis in the infarcted myocardium,
(4) inhibition of apoptosis in hearts transplanted with
TIMP-1-ES cells is mediated, in part, through the Akt
pathway, (5) transplanted TIMP-1-ES cells significantly
inhibit interstitial and vascular fibrosis as well as the
profibrotic protein, MMP-9, following MI, and (6) transplanted TIMP-1-ES cells significantly improve overall
cardiac function following MI through retention of functional cardiac myocytes and maintenance of the integrity of the host myocardium. However, future studies are
required to identify further detailed mechanisms by which
TIMP-1 prevents apoptosis and fibrosis in the infarcted
myocardium. Additionally, as TIMP-1 is a secreted factor from ES cells, future studies are warranted to assess
the role of TIMP-1-ES-CM in the infarcted myocardium, as previous studies have shown cytoprotective
effects of CM in in vitro and in vivo models of ischemic
myocardium (36,37).
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